Introduction-The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) mainly comprise polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF, primary or post-PV/ET). Therapy in PV and ET focuses on minimizing thrombosis and bleeding risk, while in MF, prolongation of survival is an important goal. Different cytoreductive agents are employed in high risk PV and ET, while the JAK inhibtior ruxolitinib is the cornerstone of therapy in MF. Histone deacetylase inhibitors (HDACi) are pleiotropic agents with diverse epigenetic and non-epigenetic actions, selectively in transformed cells. A number of HDACi have been or are being investigated in MPN.
Introduction
The term "myeloproliferative syndromes", coined by William Dameshek in 1951,(1) has classically been used to refer to chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), disorders characterized by the overproduction of mostly mature blood cells of one or more myeloid lineages. The are at least 18 human HDACs (Table 1) , grouped by their homology to yeast proteins into four classes: classes I (HDACs 1, 2, 3 and 8), II (HDACs 4, 5, 6, 7, 9 and 10) and IV (HDAC 11) all contain a zinc ion in their active site and are inhibited by the "pan"-HDACi, while the class III HDACs (sirtuins 1-7) are nicotinamide adenine dinucleotide (NAD + )-dependent enzymes that are not inhibited by currently available HDACi.(31, 32) Besides histones, HDACs deacetylate a host of non-histone proteins of fundamental importance in cancer, such as the nuclear transcription factors p53, E2F1, GATA1, FoxO3A, c-Myc and nuclear factor kappa B (NF-κB), hypoxia-inducible factor 1α (HIF-1α), the estrogen and androgen receptor complexes, the DNA repair enzymes Ku70 and WRN, the chaperone protein heat shock protein 90 (HSP90), STAT3, β-catenin, α-tubulin and the nuclear import protein importin-α7; indeed, these enzymes may be better termed "protein deacetylases", or simply "deacetylases".(31, 32) Although the most accurate nomenclature is "lysine deacetylases" (KDACs, and "lysine acetyltransferases" (KATs) rather than histone acertyltransferases (HATs) for enzymes that catalyze the opposite reaction),(35) the original terminology has largely persisted in the literature, and these enzymes and their pharmacologic inhibitors continue to be referred to as HDACs and HDACi, respectively. HDACs also have a critical role in modulating the balance between pro-and anti-apoptotic proteins, and activate death receptor pathways. Figure 1 ). Importantly, HDACi disrupt cell cycle checkpoints, induce DNA damage and proteotoxic (endoplasmic reticulum) stress, and inhibit both homologous and non-homologous end-joining (NHEJ) DNA repair mechanisms. (36) Despite their pleiotropic actions and relative selectivity for malignant cells, the clinical utility of HDACi has largely been restricted to T-cell lymphomas. Thus, the pan-HDACi, vorinostat (Zolinza®, Merck)(37) and belinostat (Beleodaq®, Spectrum),(38) and the class I HDACi romidepsin (Istodax®, Celgene)(39) are all approved for the treatment of cutaneous and/or peripheral T-cell lymphoma (CTCL/PTCL). Additionally, the pan-HDACi, panobinostat (Farydak®, Novartis), is approved in combination with bortezomib and dexamethasone for previously treated patients with multiple myeloma. HDACi have also been studied extensively in myelodysplastic sydromes (MDS) and acute myeloid leukemia (AML, but responses to monotherapy have been modest (10-20%),(40) and it does not appear that the combination of HDACi with either hypomethylating agents in MDS (41, 42) or intensive chemotherapy in AML adds therapeutic benefit. HDACi continue to be investigated in MPN in both preclinical and clinical settings. In the following sections, we summarize the current status of these agents in MPN and speculate about their future role in their therapeutic arena. 
HDACi in MPN

Preclinical data with HDACi in MPN (Table 2)
Apart from the canonical actions of JAKs in transducing cytokine signals from their cognate receptors to activate intracellular pathways,(46) JAK2 has a number of nuclear actions. Both wild type JAK2 and JAK2 V617F translocate to the nucleus and phosphorylate histone H3 (HH3) at Tyr41, thereby preventing the binding of heterochromatin protein 1 alfa (HP1α) to chromatin at this residue, leading to derepression of transcription.(47) JAK2 V617F also phosphorylates the arginine methyltransferase PRMT5, greatly impairing its ability to methylate its histone substrates and thus regulates chromatin modification by facilitating transcription, promoting myeloproliferation.(48) JAK2 additionally phosphorylates p27, an endogenous CDK inhibitor involved in cell cycle regulation, thus promoting its degradation in the cytoplasm.(49) Finally, JAK2 V617F up-regulates the CDC25A phosphatase, a key regulator of the G1/S cell cycle checkpoint, through a translational mechanism involving STAT5 and the translational initiation factor eIF2α, potentially invoking another explanation for JAK2 V617F-driven expansion of hematopoietic cells.(50) HDACi induce p21(51) and p27,(32) trigger DNA damage which transformed cells are unable to repair, (52, 53) downregulate checkpoint kinase 1 (Chk1),(54) a key regulator of the G2/M cell cycle checkpoint, interfere with the intra-S-phase(55) and mitotic spindle checkpoints (56) (57) (58) and impair multiple processes of DNA repair. (59) (60) (61) Finally, HDAC activity is required for STAT5-induced activation of transcription, (62) and panobinostat has been shown to down-regulate phospho-STAT5 (p-STAT5) and phospho-STAT3 (p-STAT3) in CTCL models in vitro and in vivo. (63) There is preclinical evidence for increased expression of HDACs in Ph-negative MPN, particularly PMF. (64, 65) The suppressor of cytokine signaling (SOCS) proteins are negative regulators of JAK-STAT signaling, competing with STATs for docking at the cytokine receptor, promoting ubiquitinylation and proteasomal degradation of JAK2, and interfering with its catalytic function.(66) Class I HDACs, primarily HDAC8, down-regulate SOCS1 and SOCS3, and HDACi inhibit JAK-STAT signaling by increasing the expression of SOCS1 and SOCS3 in primary MPN cells. (67, 68) The HDACi givinostat has been shown to inhibit proliferation of MPN cells bearing JAK2 V617F through a specific down-modulation of the JAK2 V617F protein and inhibition of its downstream signaling (i.e., phospho-JAK2 V617F, p-STAT5, p-STAT3).(69) Besides these inhibitory effects on JAK2-STAT5-extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation, givinostat also downregulates the hematopoietic transcription factors NF-E2 and C-MYB.(70) NF-E2 is often overexpressed in MPN patients, and mice expressing an NF-E2 transgene in hematopoietic cells exhibit many features of MPN, a phenotype transplantable to secondary recipient mice. (71) Givinostat and hydroxyurea at low doses potentiate each other's pro-apoptotic effects in JAK2 V617F + cell lines and are additive in freshly isolated PV cells bearing JAK2 V617F. 
Clinical trials of HDACi in MPN (Tables 3 and 4)
Givinostat (50 mg twice daily for 24 weeks) was evaluated in a pilot study in JAK2 V617F + patients with PV (n = 12), ET (n = 1) or MF (n = 16). (84) Patients with a baseline platelet count < 100 × 10 9 /L were excluded. The median treatment duration was 20 weeks and reasons for treatment discontinuation included disease progression in six patients, grade 2 thrombocytopenia in one, unrelated psychiatric symptoms in one and withdrawal of consent in two. One MF patient had a prolonged QTc at baseline and was therefore ineligible; this patient experienced a further slight QTc prolongation on study treatment, which was discontinued after day 9. Eleven PV/ET patients and seven MF patients completed 24 weeks of treatment. Dose reduction was necessary in 10 patients, and temporary withholding of the drug in 15. Among the 13 PV/ET patients, 7 (54%) had a clinical response by the 2009 European LeukemiaNet (ELN) criteria,(85) including 1 complete response (CR), and six of eight had a spleen response at the end of the study. Among the 16 patients with myelofibrosis (6 PMF + 5 post-ET MF + 5 post-PV MF), 3 (19%) achieved a major response according to EUMNET criteria,(86) but by the 2006 IWG-MRT criteria,(87) 2 patients had clinical improvement (CI) and 5 stable disease (SD). 38% of MF patients had a spleen response. The mean JAK2 V617F allele burden decreased from 55% at study entry to 47% and 41% after 12 and 24 weeks, respectively, of givinostat treatment in PV/ET patients, but there was no change among MF patients. Most toxicities were grade 1 or 2, and no grade 4 toxicity occurred. The most frequent drug-related adverse events (AEs) were diarrhea, nausea, abdominal pain, thrombocytopenia, fatigue, QTc prolongation, weight loss, anorexia and rash. Pruritus disappeared in most patients. (84) Givinostat (50 or 100 mg daily) was also tested in combination with hydroxyurea in 44 patients with PV who were unresponsive to maximum tolerated doses (MTD) of hydroxyurea in a phase II study.(88) Patients had to have JAK2 V617F + disease, and be unresponsive to hydroxyurea at the MTD for at least 3 months, as defined by the ELN.(89) Thrombocytopenia < 100 × 10 9 /L was an exclusion criterion. Treatment lasted up to 24 weeks, and assessment of response occurred at 12 and 24 weeks. Responses, by ELN 2009 criteria, (85) were achieved in 55% and 50% of patients receiving 50 or 100 mg of givinostat, respectively. Pruritus was controlled in 64% and 67% of patients in the 50 and 100 mg groups, respectively. The regimen was well tolerated: eight patients (18%) discontinued, four in each treatment arm; grade 3 AEs were reported in one patient (4.5%) in each treatment arm. The most frequent drug-related grade 2 AEs were thrombocytopenia and diarrhea. The only grade 3 toxicities were nausea and anemia in the 50 mg and 100 mg groups, respectively. No grade 4 toxicity was reported. (88) A phase II study of vorinostat (400 mg once daily) enrolled 19 patients with ET and 44 with PV.(90) There was a high discontinuation rate (52%), mainly because of non-hematologic AEs, such as fatigue, renal impairment, diarrhea, hair loss, weight loss, nausea, unspecified pain, headache and leg ulcers. 48% of patients completed 24 weeks of therapy. Most AEs reported by patients who completed the study were fatigue and gastrointestinal. The intention-to-treat response rate (RR) was 35%, and responses were independent of JAK2 mutational status among ET patients (only one PV patient was JAK2 V617F-negative).
Pruritus, present in 19% of patients at study initiation, resolved in all patients, while the prevalence of splenomegaly decreased from 50% to 27% (p = 0.03). 65% of 43 evaluable patients had a decrease in the JAK2 V617F allele burden (p = 0.006), but the median decrease among molecularly responding patients was only 5.6%, and no patient had a complete molecular response. (90) Mascarenhas et al. studied panobinostat in a phase I trial in 18 patients (10 PMF + 5 post-PV MF + 3 post-ET MF) with myelofibrosis. (91) 12 (67%) patients were positive for JAK2 V617F. Panobinostat was administered three times weekly; three successive cohorts of six patients each received 20 mg, 30 mg and 25 mg, respectively. Reversible thrombocytopenia was the dose limiting toxicity (DLT) in both the 20 mg and 30 mg dose cohorts. No patient developed clinically significant bleeding attributable to the study drug. Grade 3/4 neutropenia occurred in 17%, but there were no cases of febrile neutropenia. There were no grade 3/4 non-hematologic AEs. Diarrhea (89%), musculoskeletal AEs (33%) and fatigue (33%) were common. Only five patients received ≥6 cycles and were evaluable for response (using the 2006 IWG-MRT criteria)(87); 3 of these patients experienced CI with 100% reduction in palpable splenomegaly, and 2 SD. Two of these five patients also experienced improvement in their anemia on panobinostat. One patient had a sustained, dramatic reversal of bone marrow histopathologic abnormalities after cycles 16 and 30, and another had a significant reduction in marrow fibrosis (from grade 4 to grade 1) after 24 cycles of therapy. Most patients treated for longer than a month had symptomatic benefit, and significant reduction in splenomegaly was observed at the end of six cycles. The authors concluded that a minimum of 12 cycles of treatment with single agent panobinostat was required in order to achieve improvement in blood counts and possibly longer to achieve reversal of bone marrow histopathological abnormalities. (91) Panobinostat was also investigated in a phase II trial in myelofibrosis (n = 35, 24 PMF + 5 post-ET MF + 6 post-PV MF) at a dose of 40 mg three times a week.(92) About two-thirds (65.7%) of patients were JAK2 V617F + . 33 patients discontinued study treatment, 19 before completing cycle 3, mostly because of AEs. The median number of days on study was only 57. Twenty patients had a dose modification, and of the remaining 15, 12 had a treatment duration of < 33 days. Thrombocytopenia occurred in 71.4% of patients, and was grade 3/4 in 60%. For neutropenia, the corresponding percentages were 20% and 14.3%. Gastrointestinal AEs were extremely frequent (diarrhea, 80%; nausea, 57.1%; anorexia, 54.3%; vomiting 40%) but mostly grades 1 and 2 in severity. Fatigue occurred in 57.1% of patients, and was grade 3/4 in 31.4%. Only one patient met the 2006 IWG-MRT criteria (87) for CI. Correlative studies demonstrated increased acetylation of intracellular targets, e.g., tubacin, HH3 and HSP90, inhibition of JAK-STAT downstream signaling (p-STAT5, p-STAT3, p-AKT, phospho-mitogen activated protein kinase 3/1 (p-MAPK3/1)), downregulation of STAT5, STAT3 and AKT, anti-apoptotic PIM1 and Mcl-1 and the proinflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor α (TNFα)and MIP1β, induction of Bim and a reduction in the median JAK2 V617F allele burden from 36.82% pre-treatment to 14.88% before cycle 2 to 0.86% before cycle 4. (92) Bose and Verstovsek Page 7
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Our group has evaluated the pan-HDACi, pracinostat, at a dose of 60 mg three times weekly for three out of every four weeks in a phase II study in 22 patients with myelofibrosis.(93) 82% of patients were positive for JAK2 V617F, and the majority of patients were symptomatic at study entry and had significant palpable splenomegaly. 27% of patients experienced a reduction in splenomegaly, but none of these met the 2006 IWG-MRT criteria(87) for CI. Two patients had CI in terms of anemia. 17% of JAK2 V617F + patients had a reduction in allele burden (median 11.4%), although this was not significant when the entire cohort of JAK2 V617F + patients was analyzed as a whole. The major toxicity of pracinostat in this trial was fatigue, occurring in 91% of patients. 13% and 21% of patients, respectively, had grade 3/4 neutropenia and thrombocytopenia. At the time of publication, all but one patient had discontinued pracinostat, mostly due to lack of response or disease progression. (93) In light of these observations, and the established role of ruxolitinib in myelofibrosis, efforts are ongoing to combine HDACi such as pracinostat (NCT02267278) or panobinostat (NCT01693601, NCT01433445) with ruxolitinib. Preliminary results from a phase Ib trial of panobinostat and ruxolitinib in patients with MF have been published in abstract form. (94) Patients (n = 61, 38 escalation phase + 23 expansion phase) were required to have palpable splenomegaly ≥5 cm below the left costal margin and intermediate-1, -2 or high risk disease by the International Prognostic Scoring System,(95) and received ruxolitinib 5-15 mg twice daily and panobinostat 10-25 mg three times a week, every other week. Grade 4 thrombocytopenia and grade 3 nausea were identified as DLTs, and the higher doses of both drugs were confirmed to be the recommended phase 2 doses (RP2D). Among 34 patients treated at the RP2D, 21% discontinued due to AEs. The most common grade 3/4 hematologic AEs in these patients, regardless of attribution, were anemia (32%) and thrombocytopenia (29%), while grade 3/4 non-hematologic AEs included diarrhea (18%), asthenia (12%) and fatigue (9%). 57% and 39% of patients achieved a ≥35% reduction in spleen volume at weeks 24 and 48, respectively. 4 of 12 evaluable patients had improved bone marrow fibrosis at week 48, and 5 of 17 (29%) JAK2 V617F + patients in the expansion phase of the trial had a ≥20% decrease in allele burden by week 48. (94) 
Conclusion
HDACi are active in MPN, both preclinically and in the clinic. However, these agents have chronic, predominantly low grade, toxicities that make their long-term tolerability a concern, especially since these drugs need to be administered for long periods of time in order for disease-modifying effects to emerge, at least in MF, where the need to alter the underlying disease biology is greatest. Current development strategies are focusing on combinations with ruxolitinib, employing low doses of HDACi.
Expert Opinion
As discussed in this review, there is strong preclinical rationale and modest evidence of clinical efficacy to support the continued development of HDACi in MPN. However, considering that the MPN are chronic disorders with relatively long survival, the long-term tolerability of these drugs becomes an important concern. This is particularly relevant because the disease-modifying effects of these drugs in MF appear to take time to emerge.
In PV, a disease with a long natural history, while HDACi are clearly active, their continued development is uncertain and appears unlikely. Thrombocytopenia is an on-target effect of HDACI due to hyperacetylation of tubulin, an important constituent of the platelet microtubule cytoskeleton, leading to decreased megakaryocyte maturation and proplatelet formation, ultimately impeding the release of platelets from megakaryocytes. (101, 102) This has led some to propose development of HDACI as a treatment for ET, which is characterized by thrombocytosis.(103) However, the there is no evidence that the platelet count per se affects the risk of thrombosis or hemorrhage in ET (Falchi L, Bose P, Newberry KJ, Verstovsek S, submitted), which raises the question whether simply lowering the platelet count is a clinically relevant therapeutic goal in ET, the most indolent among the classic MPN. Risk factors for inferior survival in ET include age ≥60, leukocytosis ≥11 × 10 9 /L and prior thrombosis. The need for disease-modifying agents is greatest in MF, where ruxolitinib currently is the cornerstone of treatment. A number of JAK inhibitors have been investigated in the clinic, but many of them have been discontinued due to toxicity.(108) Of the ones still in development, pacritinib,(109) which appears to be nonmyelosuppressive, and momelotinib, (110) which may actually improve the anemia of MF, are in the most advanced stages of clinical testing; however, the "full clinical hold" recently placed on the development of pacritinib by the US Food and Drug Administration is of concern. This underscores the importance of developing rational ruxolitinib-based combinations(30). Many classes of agents are being tested, either alone or in combination with ruxolitinib: these include HDACi, DNMTi, HSP90 inhibitors, PI3K/Akt/mTOR pathway inhibitors, hedgehog inhibitors, anti-fibrotic agents and telomerase inhibitors (reviewed in ref. (111) 
Highlights box
• HDACi are active, both preclinically and clinically, in MPN.
• HDAC6 inhibitors down-regulate JAK2 and JAK2 V617F by disrupting the chaperone function of HSP90 and synergize with JAK2 inhibitors.
• HDACi have significant chronic toxicities, e.g., diarrhea, fatigue, thrombocytopenia.
• Long-term therapy is required for disease-modifying effects of HDACi in MF to emerge.
• Ongoing trials are investigating combinations of HDACi with ruxolitinib in myelofibrosis. Mechanisms of HDACi lethality. Reproduced, with permission, from (36). Table 4 Ongoing clinical trials of ruxolitinib-HDACi combinations in myelofibrosis. 
